Cargando…
Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica
Amebiasis caused by Entamoeba histolytica is the third leading cause of parasitic mortality globally, with some 100,000 deaths annually, primarily among young children. Protective immunity to amebiasis is associated with fecal IgA and IFN-γ in humans; however, no vaccine exists. We have previously i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988657/ https://www.ncbi.nlm.nih.gov/pubmed/29900011 http://dx.doi.org/10.1038/s41541-018-0060-x |
_version_ | 1783329318945947648 |
---|---|
author | Abhyankar, Mayuresh M. Orr, Mark T. Lin, Susan Suraju, Mohammed O. Simpson, Adrian Blust, Molly Pham, Tiep Guderian, Jeffrey A. Tomai, Mark A. Elvecrog, James Pedersen, Karl Petri, William A. Fox, Christopher B. |
author_facet | Abhyankar, Mayuresh M. Orr, Mark T. Lin, Susan Suraju, Mohammed O. Simpson, Adrian Blust, Molly Pham, Tiep Guderian, Jeffrey A. Tomai, Mark A. Elvecrog, James Pedersen, Karl Petri, William A. Fox, Christopher B. |
author_sort | Abhyankar, Mayuresh M. |
collection | PubMed |
description | Amebiasis caused by Entamoeba histolytica is the third leading cause of parasitic mortality globally, with some 100,000 deaths annually, primarily among young children. Protective immunity to amebiasis is associated with fecal IgA and IFN-γ in humans; however, no vaccine exists. We have previously identified recombinant LecA as a potential protective vaccine antigen. Here we describe the development of a stable, manufacturable PEGylated liposomal adjuvant formulation containing two synthetic Toll-like receptor (TLR) ligands: GLA (TLR4) and 3M-052 (TLR7/8). The liposomes stimulated production of monocyte/macrophage chemoattractants MCP-1 and Mip-1β, and Th1-associated cytokines IL-12p70 and IFN-γ from human whole blood dependent on TLR ligand composition and dose. The liposomes also demonstrated acceptable physicochemical compatibility with the recombinant LecA antigen. Whereas mice immunized with LecA and GLA-liposomes demonstrated enhanced antigen-specific fecal IgA titers, mice immunized with LecA and 3M-052-liposomes showed a stronger Th1 immune profile. Liposomes containing GLA and 3M-052 together elicited both LecA-specific fecal IgA and Th1 immune responses. Furthermore, the quality of the immune response could be modulated with modifications to the liposomal formulation based on PEG length. Compared to subcutaneous administration, the optimized liposome adjuvant composition with LecA antigen administered intranasally resulted in significantly enhanced fecal IgA, serum IgG2a, as well as systemic IFN-γ and IL-17A levels in mice. The optimized intranasal regimen provided greater than 80% protection from disease as measured by parasite antigen in the colon. This work demonstrates the physicochemical and immunological characterization of an optimized mucosal adjuvant system containing a combination of TLR ligands with complementary activities and illustrates the importance of adjuvant composition and route of delivery to enhance a multifaceted and protective immune response to amebiasis. |
format | Online Article Text |
id | pubmed-5988657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-59886572018-06-13 Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica Abhyankar, Mayuresh M. Orr, Mark T. Lin, Susan Suraju, Mohammed O. Simpson, Adrian Blust, Molly Pham, Tiep Guderian, Jeffrey A. Tomai, Mark A. Elvecrog, James Pedersen, Karl Petri, William A. Fox, Christopher B. NPJ Vaccines Article Amebiasis caused by Entamoeba histolytica is the third leading cause of parasitic mortality globally, with some 100,000 deaths annually, primarily among young children. Protective immunity to amebiasis is associated with fecal IgA and IFN-γ in humans; however, no vaccine exists. We have previously identified recombinant LecA as a potential protective vaccine antigen. Here we describe the development of a stable, manufacturable PEGylated liposomal adjuvant formulation containing two synthetic Toll-like receptor (TLR) ligands: GLA (TLR4) and 3M-052 (TLR7/8). The liposomes stimulated production of monocyte/macrophage chemoattractants MCP-1 and Mip-1β, and Th1-associated cytokines IL-12p70 and IFN-γ from human whole blood dependent on TLR ligand composition and dose. The liposomes also demonstrated acceptable physicochemical compatibility with the recombinant LecA antigen. Whereas mice immunized with LecA and GLA-liposomes demonstrated enhanced antigen-specific fecal IgA titers, mice immunized with LecA and 3M-052-liposomes showed a stronger Th1 immune profile. Liposomes containing GLA and 3M-052 together elicited both LecA-specific fecal IgA and Th1 immune responses. Furthermore, the quality of the immune response could be modulated with modifications to the liposomal formulation based on PEG length. Compared to subcutaneous administration, the optimized liposome adjuvant composition with LecA antigen administered intranasally resulted in significantly enhanced fecal IgA, serum IgG2a, as well as systemic IFN-γ and IL-17A levels in mice. The optimized intranasal regimen provided greater than 80% protection from disease as measured by parasite antigen in the colon. This work demonstrates the physicochemical and immunological characterization of an optimized mucosal adjuvant system containing a combination of TLR ligands with complementary activities and illustrates the importance of adjuvant composition and route of delivery to enhance a multifaceted and protective immune response to amebiasis. Nature Publishing Group UK 2018-06-05 /pmc/articles/PMC5988657/ /pubmed/29900011 http://dx.doi.org/10.1038/s41541-018-0060-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Abhyankar, Mayuresh M. Orr, Mark T. Lin, Susan Suraju, Mohammed O. Simpson, Adrian Blust, Molly Pham, Tiep Guderian, Jeffrey A. Tomai, Mark A. Elvecrog, James Pedersen, Karl Petri, William A. Fox, Christopher B. Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica |
title | Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica |
title_full | Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica |
title_fullStr | Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica |
title_full_unstemmed | Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica |
title_short | Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for Entamoeba histolytica |
title_sort | adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for entamoeba histolytica |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5988657/ https://www.ncbi.nlm.nih.gov/pubmed/29900011 http://dx.doi.org/10.1038/s41541-018-0060-x |
work_keys_str_mv | AT abhyankarmayureshm adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT orrmarkt adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT linsusan adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT surajumohammedo adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT simpsonadrian adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT blustmolly adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT phamtiep adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT guderianjeffreya adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT tomaimarka adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT elvecrogjames adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT pedersenkarl adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT petriwilliama adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica AT foxchristopherb adjuvantcompositionanddeliveryrouteshapeimmuneresponsequalityandprotectiveefficacyofarecombinantvaccineforentamoebahistolytica |